Protein Misfolding Cyclic Amplification for Early Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack an effective and sensitive means for early diagnosis of protein misfolding disorders, such as Alzheimer's and Parkinson's diseases, due to the challenge of detecting soluble, misfolded proteins in biological samples before irreversible neuropathological changes occur.
Innovation Solution
The Protein Misfolding Cyclic Amplification (PMCA) method involves contacting a sample with a monomeric, folded protein to form an incubation mixture, undergoing multiple cycles of incubation and physical disruption to amplify and detect soluble, misfolded proteins, excluding prion proteins, using indicators like Thioflavin T for fluorescence detection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional detection methods are used, then the detection process is simple, but the sensitivity and detection capability for soluble misfolded proteins are insufficient
Solution Approach 1:
The method performs preliminary amplification of misfolded protein seeds before detection by subjecting the sample to repeated cycles of incubation with monomeric protein and mechanical disruption, thereby increasing the concentration of detectable misfolded proteins to levels that can be reliably detected by conventional methods
Solution Approach 2:
The detection method employs periodic cycles of incubation and mechanical disruption (sonication or shaking) to repeatedly amplify misfolded protein aggregates, with each cycle converting monomeric protein to misfolded forms that can then be detected, thereby achieving high sensitivity through repeated action rather than a single complex measurement
2Reliability
If early diagnosis is attempted, then therapeutic intervention can occur before irreversible damage, but the detection of soluble misfolded proteins at this stage is extremely challenging
Solution Approach 1:
The method prepares the sample in advance by performing amplification cycles that increase the concentration of misfolded proteins to detectable levels before the actual diagnosis measurement is made, enabling reliable early detection even when initial concentrations are extremely low
Solution Approach 2:
The method uses monomeric folded protein as an intermediary substrate that converts to misfolded forms in the presence of misfolded seeds, thereby indirectly detecting the presence of pathogenic misfolded proteins at early stages when direct detection would be impossible
3Measurement precision
If amplification cycles are performed, then detection sensitivity increases, but the detection time and process complexity increase
Solution Approach 1:
The method optimizes detection time by controlling parameters such as incubation temperature, monomeric protein concentration, and mechanical disruption intensity to achieve sufficient amplification in a practical time frame rather than allowing unlimited amplification time
Solution Approach 2:
The method uses periodic cycles of incubation and disruption that can be performed in parallel or sequentially, with each cycle contributing to amplification while maintaining a manageable overall time through efficient cycling rather than continuous prolonged processing
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
PMCA enables ultra-sensitive detection of misfolded aggregates, distinguishing between diseased and non-diseased samples with high sensitivity and specificity, facilitating early diagnosis and potential therapeutic monitoring.
Implementation Method 1
determining the presence of the soluble, misfolded protein in the sample by detecting a fluorescence of the Thioflavin T corresponding to soluble, misfolded protein
Data Source
AI summary
Methods and kits are provided for amplifying and detecting misfolded proteins from samples, for example, from patients having Alzheimer's Disease, Parkinson's Disease, and the like. For example, a method for determining a presence of soluble, misfolded protein in a sample may include contacting the sample with a monomeric, folded protein to form an incubation mixture; conducting an incubation cycle two or more times effective to form an amplified portion of misfolded protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded protein; physically disrupting the incubation mixture effective to break up at least a portion of any protein aggregate present; and determining the presence of the soluble, misfolded protein in the sample by detecting at least a portion of the soluble, misfolded protein. The monomeric, folded protein and the soluble, misfolded protein may exclude prion protein (PrP) and isoforms thereof.